Treatment-induced Expression of Anti-apoptotic Proteins in WSU-CLL, a Human Chronic Lymphocytic Leukemia Cell Line

References

• Ahmed I., Al-Katib A., Beck F. W.J, Mohammad R. M. Sequential treatment of a resistant CLL-patient with Bryostatin 1 followed by 2-deoxychloro-adenosine: case report. Clin. Cancer Res. 2000; 5: 1328–1332
   Google Scholar
• Al-Katib A., Mohammad R. M., Dan M., Hussein M. E., Akhtar A., Pettit G. R., Sensenbrenner L. L. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells. “in vitro”, Exp. Hematol. 1993; 21: 61–65
   PubMed Web of Science ®Google Scholar
• Ambrosini G., Adida C., Altieri D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997; 3: 917–921
   PubMed Web of Science ®Google Scholar
• Beck F. W.J., Al-Katib A. M., Ahmad I., Wall N. R., Liu K.-Z., Mantch H. H., Mohammad R. M. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlor-odeoxyadenosine influx in WSU-CLL. Int. J. Mol. Med. 2000; 5: 341–347
   PubMed Web of Science ®Google Scholar
• Datta S. R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–241
   PubMed Web of Science ®Google Scholar
• Del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687–689
   PubMed Web of Science ®Google Scholar
• De Rossi G., Mauro F. R., Caruso R., Monarca B., Mandelli F. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica 1993; 78: 167–171
   PubMed Web of Science ®Google Scholar
• Deveraux Q. L., Reed J. C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999; 13: 239–252
   PubMed Web of Science ®Google Scholar
• Deveraux Q. L., Roy N., Stennicke H. R., Van Arsdale T., Zhou Q., Srinivasula S. M., Salvesen G. S., Reed J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998; 17: 2215–2223
   PubMed Web of Science ®Google Scholar
• Dighiero G., Travade P., Chevret S., Fenaux P., Chastang C., Binet J.-L. The French cooperative group on CLL: B-cell chronic lymphocytic leukaemia: present status and future directions. Blood 1991; 78: 1901–1914
   PubMed Web of Science ®Google Scholar
• Duckett C. S., Nava V. E., Gedrich R. W., Clem RJ., Van Dongen J. L., Gilfillan M. C., Shiels H., Hardwick J. M., Thompson C. B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996; 15: 2685–2689
   PubMed Web of Science ®Google Scholar
• Erl W., Hansson G. K., De Martin R., Draude G., Weber K. S.C., Weber C. Nuclear factor-KB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 1999; 84: 668–677
   PubMed Web of Science ®Google Scholar
• Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: new insights in biology and therapy. Ann. Int. Med. 1990; 11352: 5–113539
   Google Scholar
• Genini D., Budihardjo I., Plunkett W., Wang X., Carrera C. J., Cottam H. B., Carson D. A., Leoni L. M. Nucleotide requirement for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem. 2000; 275: 29–34
   PubMed Web of Science ®Google Scholar
• Hauser H. P., Bardroff M., Pyrowolakis G., Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell. Biol. 1998; 141: 1415–1422
   PubMed Web of Science ®Google Scholar
• Ho A. D., Thaler J., Stryckmans P., Coiffier B., Luciani M., Sonneveld P., Lechner K., Rodenhuis S., Peetermans M. E., DeCataldo F. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European organization for research and treatment of cancer. J. Natl. Cancer Inst. 1990; 82: 1416–1420
   PubMed Web of Science ®Google Scholar
• Jones R. J., Sharkis S. J., Miller C. B., Towinsky E. K., Burke P. J., May W. S. Bryostatin 1, a unique biological response modifier: antileukemic activity. “in vitro”, Blood 1990; 75: 1319–1323
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1993; 11: 679–689
   PubMed Web of Science ®Google Scholar
• Kawasaki H., Carrera C. J., Piro L. D., Sanen A., Kipps T. J., Carson D. A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597–601
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Kemena A., O'Brien S., Kantarjian H., Robertson L., Koller C., Beran M., Estey E., Plunkett W., Lerner S., Keating M. J. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 1993; 10: 187–193
   PubMed Web of Science ®Google Scholar
• Kiss Z., Deli E., Girard P. R., Pettit G. R., Kuo J. F. Comparative effects of polymyxin B, phorbol ester and bryostatin on protein phosphorylation, protein kinase C translocation, phospholipid metabolism and differentiation of HL60 cells. Biochem. Biophys. Res. Commun. 1987; 146: 208–215
   PubMed Web of Science ®Google Scholar
• Kitada S., Zapata J. M., Andreeff M., Reed J. C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1999; 106: 995–1004
   PubMed Web of Science ®Google Scholar
• LaCasse E. C., Baird S., Korneluk R. G., MacKenzie A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–3259
   PubMed Web of Science ®Google Scholar
• Levkau B., Garton K. J., Ferri N., Kloke K., Nofer J.-R., Baba H. A., Raines E. W., Breithardt G. XIAP induces cell-cycle arrest and activates nuclear factor-kb: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ. Res. 2001; 88: 282–290
   PubMed Web of Science ®Google Scholar
• Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580–584
   PubMed Web of Science ®Google Scholar
• Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J. E., MacKenzie A., Korneluk R. G. Suppression of apoptosis in mammalian cells by NATP and a related family of IAP genes. Nature 1996; 379: 349–353
   PubMed Web of Science ®Google Scholar
• Liu X., Kim C. N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
   PubMed Web of Science ®Google Scholar
• Mansson E., Spasokoukotskaja T., Sallstrom J., Eriksson S., Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 1999; 59: 5956–5963
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Diwakaran H., Maki A., Emara M. A., Pettit G. R., Redman B., Al-Katib A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Res. 1995; 19: 667–673
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Mohamed A. N., Hamdan M. Y., Vo T., Chen B., Katato K., Abubakr Y. A., Dugan M. C., Al-Katib A. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996; 10: 130–137
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Beck F. W., Katato K., Hamdy N., Wall N., Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol Chem. 1998; 379: 1253–1261
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A., Fulton D., Mahboubi K., Kalb R. G., O'Connor D. S., Li F., Altieri D. C., Sessa W. C. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol Chem. 2000; 275: 9102–9105
   PubMed Web of Science ®Google Scholar
• Paterson A. R.P., Brown R. D., Gibson J., Pope B., Luo X-F., Schutz L., Wiley J. S., Joshua D. E. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues. “in vitro”, Eur. J. Haemotol. 1996; 56: 213–220
   PubMed Web of Science ®Google Scholar
• Pettit G. R., Herald S. L., Doubek D. L., Arnold E., Clardy J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 1982; 104: 6846–6848
   Web of Science ®Google Scholar
• Rothe M., Pan M.-G., Henzel W. J., Ayres T. M., Goeddel D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243–1252
   PubMed Web of Science ®Google Scholar
• Roy N., Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997; 16: 6914–6925
   PubMed Web of Science ®Google Scholar
• Slee E. A., Harte M. T., Kluck R. M., Wolf B. B., Casiano C. A., Newmeyer D. D., Wang H-G., Reed J. C., Nicholson D. W., Alnemri E. S., Green D. R., Martin S. J. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases 2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 1999; 144: 281–292
   PubMed Web of Science ®Google Scholar
• Stone R. M., Sariban E., Pettit G. R., Kufe D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72: 208–213
   PubMed Web of Science ®Google Scholar
• Tefferi A., Phyliky R. L. A clinical update on chronic lymphocytic leukemia. Diagnosis and prognosis. Mayo Clin. Pro. 1992a; 67: 349–353
   PubMed Web of Science ®Google Scholar
• Tefferi A., Phyliky R. L. A clinical update on chronic lymphocytic leukemia. Critical analysis of current chemotherapeutic modalities. Mayo Clin. Pro. 1992b; 67: 457–461
   PubMed Web of Science ®Google Scholar
• Thornberry N. A., Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312–1316
   PubMed Web of Science ®Google Scholar
• Trentin L., Zambello R., Agostini C., Enthammer C., Cerutti A., Adami E., Zamboni S., Semenzato G. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoetic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 4249–4256
   PubMed Web of Science ®Google Scholar
• Uren A. G., Pakusch M., Hawkins C. J., Puis K. L., Vaux D. L. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc. Natl. Acad. Sci. USA 1996; 93: 4974–4978
   PubMed Web of Science ®Google Scholar
• Wagenknecht B., Glaser T., Naumann U., Kugler S., Isenmann S., Bahr M., Korneluk R., Liston P., Weller M. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 1999; 6: 370–376
   PubMed Web of Science ®Google Scholar
• Wall N. R., Mohammad R. M., Nabha S. M., Pettit G. R., Al-Katib A. M. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 result in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, reh. Biochem. Biophys. Res. Commun. 1999; 266: 76–80
   PubMed Web of Science ®Google Scholar
• Wang C. Y., Mayo M. W., Korneluk R. G., Goeddel D. V., Baldwin A. S., Jr. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680–1683
   PubMed Web of Science ®Google Scholar
• Yang E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285–291
   PubMed Web of Science ®Google Scholar
• Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3–3 not BCL-X. Cell 1996; 87: 619–628
   PubMed Web of Science ®Google Scholar